LIVN (LivaNova PLC) — AI Stock Analysis & Recommendation

Research of August 4, 2026 · Healthcare / Electromedical & Electrotherapeutic Apparatus

TradeFlare's AI research teams rate LIVN a STRONG BUY. The latest price is $76.37.

The research plan

• Entry: $84.75
• Target: $92.23
• Stop: $72.04
• Time horizon: weeks

The 52-week breakout suggests momentum that can carry for several weeks in a bull market.

Why

LIVN presents a high-conviction 52-week breakout setup in a bull market, supported by strong sentiment and technicals. However, the bearish fundamentals and high risk score necessitate a cautious approach with a small position size and a tight stop loss. The R/R is slightly below the ideal 1.5, but the strong technical breakout and market regime warrant a tactical entry.

What could push LIVN higher

• Breakout above 52-week high with increased volume, indicating strong buying interest.
• Positive retail and analyst sentiment driven by recent performance and price target hikes.
• Bull market environment generally supports opportunistic breakouts.

Key risks for LIVN

• Deteriorating fundamental metrics like net loss and cash flow issues.
• Mixed momentum indicators (MACD, Stochastic) showing bearish signals despite the bullish trend.
• High risk score and elevated short interest (high days to cover) suggest potential volatility.

What each AI research team found

Fundamental team: Bearish · valuation: overvalued

LIVN is currently overvalued given its significant net losses and deteriorating quarterly cash flows, despite positive revenue growth. The high trailing P/E and above-industry EV/EBITDA suggest the market is anticipating a strong earnings recovery that is not yet supported by fundamentals, making the current price unsustainable.

• Significant net loss of -$242M in FY2025 despite 14.3% revenue growth, indicating profitability challenges.
• Deteriorating quarterly free cash flow ($0.9M) and operating cash flow ($15.2M) signal potential cash generation issues.
• High trailing P/E of 43.53, coupled with a forward P/E of 18.42, suggests the market is pricing in substantial earnings recovery that is not yet evident.

Technical team: Bullish

Despite mixed momentum signals, the strong uptrend and bullish chart patterns suggest a high probability of a breakout above current resistance. The stock is trading near its 52-week high with increased volume, reinforcing the bullish outlook. A stop loss below the nearest support level provides a defined risk.

• The uptrend is strong with price above key moving averages, but the price is approaching resistance, suggesting potential consolidation before further upside.
• Volume has been fluctuating with spikes above the 20-day MA on up days, indicating some buying interest amidst consolidation near resistance.
• Momentum indicators are mixed; MACD and Stochastic show bearish signals, while RSI is neutral, and the price is consolidating.

Sentiment team: Bullish

LIVN exhibits a strong positive sentiment driven by a combination of analyst upgrades, institutional accumulation, and positive product developments like the FDA approval for the aura6000 System. While some concerns exist regarding near-term price targets, the overall momentum and breadth of positive catalysts suggest a bullish outlook.

• LivaNova's news coverage is largely neutral, with a slightly positive overall sentiment score driven by recent stock performance, an analyst upgrade, and FDA approval for a key product, though a lack of overwhelmingly positive news prevents a stronger...
• LivaNova (LIVN) is experiencing positive retail sentiment driven by strong earnings, FDA approvals, and favorable analyst ratings, despite some concerns about near-term price targets. (Score: 0.15)
• LivaNova exhibits a strong positive sentiment driven by a "Moderate Buy" consensus, recent price target hikes, and significant institutional accumulation, despite minor concerns about near-term price targets and potential growth headwinds. (Consensus: Moderate Buy)

Risk team: High

LIVN presents a high-risk profile due to its significant historical drawdowns, elevated volatility, and potential short squeeze risk. The dependence on innovation and salesforce effectiveness adds company-specific vulnerability. Given these factors, a small position size with a tight stop-loss is recommended to manage the substantial downside potential.

• Deep 1-Year Drawdown and High Volatility: The stock has experienced a significant drawdown of nearly 50% in the past year, coupled with elevated realized volatility (20d annualized: 32.16%), indicating substantial downside risk and potential for large price swings.
• High Days to Cover: The 'high_days_to_cover_gt_5' flag suggests a potentially elevated short interest relative to liquidity, which can amplify price volatility and increase the risk of short squeezes or sharp sell-offs.
• Business Model Dependence on Innovation and Salesforce: LIVN's business model relies heavily on continuous innovation and the effectiveness of its salesforce. Failure in these areas could significantly impact revenue and market position.

LIVN at a glance

Market value	$4.1B
Price / earnings	21.8
Revenue growth (year over year)	12.4%
Profit margin	12.8%
Debt / equity	0.22

TradeFlare's published calls on LIVN

• February 26, 2026: hit stop, -7.5%
• February 27, 2026: hit stop, -7.5%

Every AI call on LIVN since February 25, 2026, and what happened next (5 calls) →

Research of August 4, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.